Menu
Back to User profile » Dr Lynn Webster
Papers published by Dr Lynn Webster:
Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies
Camilleri M, Hale M, Morlion B, Tack J, Webster L, Wild J
Journal of Pain Research 2021, 14:2179-2189
Published Date: 16 July 2021
A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
Webster LR, Hale ME, Yamada T, Wild JE
Journal of Pain Research 2020, 13:605-612
Published Date: 24 March 2020
Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone
Webster LR, Israel RJ
Journal of Pain Research 2018, 11:2509-2516
Published Date: 23 October 2018
Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain
Webster LR, Israel RJ
Journal of Pain Research 2018, 11:1503-1510
Published Date: 13 August 2018
Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP
Journal of Pain Research 2018, 11:1163-1164
Published Date: 19 June 2018
Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals
Webster LR, Camilleri M, Finn A
Substance Abuse and Rehabilitation 2016, 7:81-86
Published Date: 14 June 2016
Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
Webster LR, Smith MD, Unal C, Finn A
Journal of Pain Research 2015, 8:791-798
Published Date: 4 November 2015
Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP
Journal of Pain Research 2015, 8:771-780
Published Date: 30 October 2015
The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability
Schatman ME, Webster LR
Journal of Pain Research 2015, 8:153-158
Published Date: 18 March 2015
Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users
Webster LR, Rolleri RL, Pixton GC, Sommerville KW
Substance Abuse and Rehabilitation 2012, 3:101-113
Published Date: 17 August 2012
Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain
Webster LR, Peppin JF, Murphy FT, Tobias JK, Vanhove GF
Journal of Pain Research 2012, 5:7-13
Published Date: 20 January 2012
Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain
Peppin JF, Majors K, Webster LR, Simpson DM, Tobias JK, Vanhove GF
Journal of Pain Research 2011, 4:385-392
Published Date: 14 November 2011
Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting
Brown J, Setnik B, Lee K, Cleveland JM, Roland CL, Wase L, Webster L
Journal of Pain Research 2011, 4:373-384
Published Date: 8 November 2011